
TEM Stock Forecast & Price Target
TEM Analyst Ratings
Bulls say
Tempus AI is positioned for strong revenue growth through their unique combination of AI technology, real-world data, and value-added services. With FDA approval for their xT CDx platform and plans for expansion into other areas, their data business is expected to see significant growth. While risks such as volatile ordering patterns and government funding may present challenges, their focus on margin-accretive data revenue and expansion within the pharmaceutical industry puts them in a positive outlook for the future.
Bears say
Tempus AI is expected to experience 25%+ growth in the coming years, driven by FDA approval for tumor-only xT CDx and favorable pricing dynamics. Additionally, the company has a strong data and applications business, with a target of $650M in revenue by 2028. However, there are potential risks related to its commercial partner and volatility in budgets and ordering patterns from pharma companies. While the company has achieved positive cash flow and has a promising technology platform according to medical oncologists, there may be execution and focus risks in the future.
This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares